Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice
Anti-inflammatory and antidiabetogenic properties have been ascribed to cannabidiol (CBD). CBD-based medicinal drugs have been approved for over a lustrum, and a boom in the commercialization of CBD products started in parallel. Herein, we explored the efficacy of CBD in streptozotocin (STZ)-induced...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/9/863 |
| _version_ | 1797517622775906304 |
|---|---|
| author | Beatriz Carmona-Hidalgo Adela García-Martín Eduardo Muñoz Isabel González-Mariscal |
| author_facet | Beatriz Carmona-Hidalgo Adela García-Martín Eduardo Muñoz Isabel González-Mariscal |
| author_sort | Beatriz Carmona-Hidalgo |
| collection | DOAJ |
| description | Anti-inflammatory and antidiabetogenic properties have been ascribed to cannabidiol (CBD). CBD-based medicinal drugs have been approved for over a lustrum, and a boom in the commercialization of CBD products started in parallel. Herein, we explored the efficacy of CBD in streptozotocin (STZ)-induced diabetic mice to prevent diabetic nephropathy at onset. Eight-to-ten-week-old C57BL6J male mice were treated daily intraperitoneally with 10 mg/kg of CBD or vehicle for 14 days. After 8 days of treatment, mice were challenged with STZ or vehicle (healthy-control). At the end of the study, non-fasting blood glucose (FBG) level was 276 ± 42 mg/dL in vehicle-STZ-treated compared to 147 ± 9 mg/dL (<i>p</i> ≤ 0.01) in healthy-control mice. FBG was 114 ± 8 mg/dL in vehicle-STZ-treated compared to 89 ± 4 mg/dL in healthy-control mice (<i>p</i> ≤ 0.05). CBD treatment did not prevent STZ-induced hyperglycemia, and non-FBG and FBG levels were 341 ± 40 and 133 ± 26 mg/dL, respectively. Additionally, treatment with CBD did not avert STZ-induced glucose intolerance or pancreatic beta cell mass loss compared to vehicle-STZ-treated mice. Anatomopathological examination showed that kidneys from vehicle-STZ-treated mice had a 35% increase of glomerular size compared to healthy-control mice (<i>p</i> ≤ 0.001) and presented lesions with a 43% increase in fibrosis and T cell infiltration (<i>p</i> ≤ 0.001). Although treatment with CBD prevented glomerular hypertrophy and reduced T cell infiltration, it significantly worsened overall renal damage (<i>p</i> ≤ 0.05 compared to vehicle-STZ mice), leading to a more severe renal dysfunction than STZ alone. In conclusion, we showed that CBD could be detrimental for patients with type 1 diabetes, particularly those undergoing complications such as diabetic nephropathy. |
| first_indexed | 2024-03-10T07:19:06Z |
| format | Article |
| id | doaj.art-367930f58d464d869c1c815267217785 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T07:19:06Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-367930f58d464d869c1c8152672177852023-11-22T14:44:32ZengMDPI AGPharmaceuticals1424-82472021-08-0114986310.3390/ph14090863Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male MiceBeatriz Carmona-Hidalgo0Adela García-Martín1Eduardo Muñoz2Isabel González-Mariscal3Emerald Health Biotechnology, 14014 Córdoba, SpainEmerald Health Biotechnology, 14014 Córdoba, SpainInstituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Hospital Universitario Reina Sofía, 14004 Córdoba, SpainInstituto de Investigación Biomédica de Málaga-IBIMA, UGC Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, 29009 Málaga, SpainAnti-inflammatory and antidiabetogenic properties have been ascribed to cannabidiol (CBD). CBD-based medicinal drugs have been approved for over a lustrum, and a boom in the commercialization of CBD products started in parallel. Herein, we explored the efficacy of CBD in streptozotocin (STZ)-induced diabetic mice to prevent diabetic nephropathy at onset. Eight-to-ten-week-old C57BL6J male mice were treated daily intraperitoneally with 10 mg/kg of CBD or vehicle for 14 days. After 8 days of treatment, mice were challenged with STZ or vehicle (healthy-control). At the end of the study, non-fasting blood glucose (FBG) level was 276 ± 42 mg/dL in vehicle-STZ-treated compared to 147 ± 9 mg/dL (<i>p</i> ≤ 0.01) in healthy-control mice. FBG was 114 ± 8 mg/dL in vehicle-STZ-treated compared to 89 ± 4 mg/dL in healthy-control mice (<i>p</i> ≤ 0.05). CBD treatment did not prevent STZ-induced hyperglycemia, and non-FBG and FBG levels were 341 ± 40 and 133 ± 26 mg/dL, respectively. Additionally, treatment with CBD did not avert STZ-induced glucose intolerance or pancreatic beta cell mass loss compared to vehicle-STZ-treated mice. Anatomopathological examination showed that kidneys from vehicle-STZ-treated mice had a 35% increase of glomerular size compared to healthy-control mice (<i>p</i> ≤ 0.001) and presented lesions with a 43% increase in fibrosis and T cell infiltration (<i>p</i> ≤ 0.001). Although treatment with CBD prevented glomerular hypertrophy and reduced T cell infiltration, it significantly worsened overall renal damage (<i>p</i> ≤ 0.05 compared to vehicle-STZ mice), leading to a more severe renal dysfunction than STZ alone. In conclusion, we showed that CBD could be detrimental for patients with type 1 diabetes, particularly those undergoing complications such as diabetic nephropathy.https://www.mdpi.com/1424-8247/14/9/863cannabinoidstreptozotocinphytocannabinoidtype 1 diabetesendocannabinoid systemchronic kidney disease |
| spellingShingle | Beatriz Carmona-Hidalgo Adela García-Martín Eduardo Muñoz Isabel González-Mariscal Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice Pharmaceuticals cannabinoid streptozotocin phytocannabinoid type 1 diabetes endocannabinoid system chronic kidney disease |
| title | Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice |
| title_full | Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice |
| title_fullStr | Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice |
| title_full_unstemmed | Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice |
| title_short | Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice |
| title_sort | detrimental effect of cannabidiol on the early onset of diabetic nephropathy in male mice |
| topic | cannabinoid streptozotocin phytocannabinoid type 1 diabetes endocannabinoid system chronic kidney disease |
| url | https://www.mdpi.com/1424-8247/14/9/863 |
| work_keys_str_mv | AT beatrizcarmonahidalgo detrimentaleffectofcannabidiolontheearlyonsetofdiabeticnephropathyinmalemice AT adelagarciamartin detrimentaleffectofcannabidiolontheearlyonsetofdiabeticnephropathyinmalemice AT eduardomunoz detrimentaleffectofcannabidiolontheearlyonsetofdiabeticnephropathyinmalemice AT isabelgonzalezmariscal detrimentaleffectofcannabidiolontheearlyonsetofdiabeticnephropathyinmalemice |